重新思考转运体药物相互作用风险的静态分析框架:整合生物标志物生成泛转运体抑制特征
溶质载体(SLC)转运体是重要药物相互作用(DDI)的位点,申办方通常用体外IC50数据和监管机构指导的静态方法评估DDI风险,但该方法保守且假阳性率高。本文通过生成多种临床生物标志物合格 perpetrator 药物的体外SLC IC50数据,估算各SLC的抑制百分比并与已发表临床生物标志物数据经验性关联,经校准后发现仅R值>1.5且Cmax,u/IC50>0.5的化合物可能显著调节肝(AUCR>1.25)和肾(ΔCLrenal>25%)生物标志物并引发DDI风险。该抑制百分比方法支持整合肝和肾SLC数据,生成泛SLC抑制特征,指导I期研究中生物标志物的选择。
要点
- 静态法阈值(肝SLC R≥1.04、肾SLC Cmax,u/IC50≥0.02)易致假阳性。
- 仅R>1.5且Cmax,u/IC50>0.5的化合物可能显著调节肝(AUCR>1.25)和肾(ΔCLrenal>25%)生物标志物。
- 抑制百分比方法可生成泛SLC抑制特征,指导I期生物标志物选择。
核心结论
- 整合肝和肾SLC数据的抑制百分比方法可生成泛SLC抑制特征,指导I期研究中生物标志物的选择。
- 仅高R值(>1.5)和高Cmax,u/IC50比值(>0.5)的化合物可能显著调节肝和肾生物标志物并引发DDI风险。
研究设计与样本
- 在标准实验条件下生成多种临床生物标志物合格perpetrator药物的体外SLC IC50数据,估算各SLC的抑制百分比,并与已发表临床生物标志物数据经验性关联。
主要发现
- 仅R值>1.5且Cmax,u/IC50>0.5的化合物可能显著调节肝(AUCR>1.25)和肾(ΔCLrenal>25%)生物标志物并引发DDI风险。
- 抑制百分比方法支持整合肝和肾SLC数据,生成泛SLC抑制特征(如SLC抑制百分比排序)。
关键数值与推荐
- 肝SLC R值≥1.04和肾SLC Cmax,u/IC50比值≥0.02的静态法阈值可能触发DDI研究但假阳性率高。
- R值>1.5且Cmax,u/IC50>0.5的化合物可能显著调节肝(AUCR>1.25)和肾(ΔCLrenal>25%)生物标志物。
临床怎么用
- 在I期研究中利用血浆和尿液SLC生物标志物降低DDI风险,避免基于药物探针的研究。
- 根据泛SLC抑制特征选择最合适的单个或组合生物标志物进行I期测试。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Solute carrier (SLC) transporters present as the loci of important drug-drug interactions (DDIs). Therefore, sponsors generate in vitro half-maximal inhibitory concentration (IC50 ) data and apply regulatory agency-guided "static" methods to assess DDI risk and the need for a formal clinical DDI study. Because such methods are conservative and high false-positive rates are likely (e.g., DDI study triggered when liver SLC R value ≥ 1.04 and renal SLC maximal unbound plasma (Cmax,u )/IC50 ratio ≥ 0.02), investigators have attempted to deploy plasma- and urine-based SLC biomarkers in phase I studies to de-risk DDI and obviate the need for drug probe-based studies. In this regard, it was possible to generate in-house in vitro SLC IC50 data for various clinically (biomarker)-qualified perpetrator drugs, under standard assay conditions, and then estimate "% inhibition" for each SLC and relate it empirically to published clinical biomarker data (area under the plasma concentration vs. time curve (AUC) ratio (AUCR, AUCinhibitor /AUCreference ) and % decrease in renal clearance (ΔCLrenal )). After such a "calibration" exercise, it was determined that only compounds with high R values (> 1.5) and Cmax,u /IC50 ratios (> 0.5) are likely to significantly modulate liver (AUCR > 1.25) and renal (ΔCLrenal > 25%) biomarkers and evoke DDI risk. The % inhibition approach supports integration of liver and renal SLC data and allows one to generate pan-SLC inhibition signatures for different test perpetrators (e.g., SLC % inhibition ranking). In turn, such signatures can guide the selection of the most appropriate individual (or combinations of) biomarkers for testing in phase I studies.
引用
- Rodrigues AD. Reimagining the Framework Supporting the Static Analysis of Transporter Drug Interaction Risk; Integrated Use of Biomarkers to Generate Pan-Transporter Inhibition Signatures. Clin Pharmacol Ther. 2022. PMID: 35869864. doi:10.1002/cpt.2713
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。